Literature DB >> 2621455

Epidemiology of human T-cell leukaemia/lymphoma virus type 1 (HTLV-1) infections in a subpopulation of Afro-Caribbean origin in England.

J Mowbray1, S Mawson, A Chawira, S Skidmore, E Boxall, U Desselberger, S Nightingale.   

Abstract

Epidemiological studies on neurological diseases in residents of Afro-Caribbean origin in the West Midlands region of England have identified eight patients with tropical spastic paraparesis (TSP), all of whom were found to be infected with human T-cell leukaemia/lymphoma virus type 1 (HTLV-1). The husband of one of the patients with TSP was also infected with HTLV-1 and had a T-cell lymphoma. In addition, six asymptomatic HTLV-1-infected first-degree relatives of the TSP patients have been found. By anonymous testing of over 700 sera obtained from individuals of Afro-Caribbean, African, or Asian ethnic origin, seven HTLV-1-infected individuals were detected, who were all immigrants from the Caribbean. Overall, these numbers yielded a seroprevalence of HTLV-1 infections of 3.4% among the immigrant population of Afro-Caribbean origin, which is comparable with the prevalence of HTLV-1 in Jamaica in an equivalent age and sex cohort. Sera were tested for HTLV-1 antibody by means of three different procedures: passive particle agglutination test (Serodia), indirect enzyme-labeled immunosorbent assay (ELISA; Dupont), and indirect immunofluorescence test (in-house, using HTLV-1-infected MT2 cells). The results of all three tests correlated very well with each other. HTLV-1 antibody titres in TSP patients were on the whole significantly higher than those of asymptomatic carriers, but some of the apparently healthy first-degree relatives and one anonymously tested individual had titres as high as most of the TSP patients.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2621455     DOI: 10.1002/jmv.1890290413

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  HTLV-I infection in Britain.

Authors: 
Journal:  BMJ       Date:  1990-09-01

2.  HTLV-I infection in British and Jamaican relatives of British patients with tropical spastic paraparesis.

Authors:  S Nightingale; U Desselberger
Journal:  BMJ       Date:  1990-03-10

3.  Infection with human T cell leukaemia/lymphoma virus type I in patients attending an antenatal clinic in London.

Authors:  J H Tosswill; A E Ades; C Peckham; P P Mortimer; J N Weber
Journal:  BMJ       Date:  1990-07-14

4.  Expression of human T lymphotropic virus type 1 (HTLV-1) tax/rex gene in fresh bronchoalveolar lavage cells of HTLV-1-infected individuals.

Authors:  Y Higashiyama; S Katamine; S Kohno; H Mukae; S Hino; T Miyamoto; K Hara
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

5.  Antenatal survey for the seroprevalence of HTLV-1 infections in the West Midlands, England.

Authors:  S Nightingale; D Orton; D Ratcliffe; S Skidmore; J Tosswill; U Desselberger
Journal:  Epidemiol Infect       Date:  1993-04       Impact factor: 2.451

6.  Prevalence of antibody to human T-cell lymphotropic virus type I/II in people of Caribbean origin in Toronto.

Authors:  J Chiavetta; J Nusbacher; F Tam; A Wall; J Steaffens; H Lee
Journal:  CMAJ       Date:  1992-11-15       Impact factor: 8.262

7.  Epidemiological Aspects and World Distribution of HTLV-1 Infection.

Authors:  Antoine Gessain; Olivier Cassar
Journal:  Front Microbiol       Date:  2012-11-15       Impact factor: 5.640

Review 8.  Family Aggregation of Human T-Lymphotropic Virus 1-Associated Diseases: A Systematic Review.

Authors:  Carolina Alvarez; Eduardo Gotuzzo; Anne-Mieke Vandamme; Kristien Verdonck
Journal:  Front Microbiol       Date:  2016-10-28       Impact factor: 5.640

9.  HTLV-1 infection in solid organ transplant donors and recipients in Spain.

Authors:  Carmen de Mendoza; Lourdes Roc; Rafael Benito; Gabriel Reina; José Manuel Ramos; Cesar Gómez; Antonio Aguilera; Manuel Rodríguez-Iglesias; Juan García-Costa; Miriam Fernández-Alonso; Vicente Soriano
Journal:  BMC Infect Dis       Date:  2019-08-09       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.